Tilray Brands, Inc. said on Monday that its Germany-based cannabis cultivation facility, Aphria RX GmbH, had received a cultivation license under Germany’s new adult-use cannabis legalization law.
Aphria RX was licensed in 2019 to grow cannabis for Germany’s medical cannabis program but with its newest license, the company is authorized to cultivate and manufacture even more products. Additionally, the cultivator is expanding its genetics from the three strains previously approved for the medical cannabis program to 31 approved strains under the Cannabis Act.
“We are thrilled to receive this license as it will provide greater access to some of the highest quality medical cannabis produced in Germany and enable us to expand the range of treatment options available to patients. We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care.” — Denise Faltischek, Chief Strategy Officer and Head of International for Tilray, in a press release
Germany’s adult-use cannabis legalization law took effect on April 1. Under the law, cannabis was removed from Germany’s Narcotics List, and adults aged 18 and older are now allowed to possess and consume cannabis. The proposal initially included regulated adult-use sales but lawmakers walked back their plans for a fully regulated marketplace.
Cannabis access is, for now, largely limited to homegrown supplies although new cannabis clubs launched this month, through which a limited number of members can legally source their cannabis.
Get daily cannabis business news updates. Subscribe
Ganjapreneur is made possible by our partners:
